UTHSC Professor Receives Grant To Study Ormeloxifene As Prostate Cancer Treatment

UTHSC Professor Receives Grant To Study Ormeloxifene As Prostate Cancer Treatment
shutterstock_147278594The U.S. Department of Defense will provide a $562,500 grant for Dr. Subhash Chauhan, a professor in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Tennessee Health Science Center (UTHSC), to study ormeloxifene as a treatment for advanced prostate cancer. Originally a birth control drug, this selective estrogen receptor modulator will be tested to stop prostate tumor growth and development. “Metastatic prostate cancer is a major clinical challenge. We are trying to develop a therapeutic drug that can inhibit prostate cancer metastasis via suppression of a master oncogenic signaling pathway. Inhibition of this pathway will eventually inhibit several other cancer metastasis-associated genes to suppress the process of cancer spreading,” Dr. Chauhan said in a Memphis Daily News interview. Dr. Chauhan and Dr. Meena Jaggi, an associate Professor of Pharmaceutical Sciences at UTHSC, along with a team of 10 researchers, will lead the study. The team had already published some of their work in The Journal of Cancer Research, whereby they demonstrated the capacity
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *